Company intelligence / Profile preview

Prota Therapeutics

Melbourne, Victoria, Australiaprotatherapeutics.com ↗

Ownership: Private
Employees: ~10
Development stage: Phase 3

Overview

Prota Therapeutics has demonstrated in a long-term Phase 2b follow-on study that its remission-inducing high-dose peanut oral immunotherapy treatments provide significant and sustained benefits for patients with peanut allergy. These include reduced frequency and severity of allergic reactions, improved health-related quality of life, and lasting psychological benefits. The company’s lead product, PRT120, has shown durable clinical remission post-treatment compared to placebo or desensitization alone. A pivotal Phase 3 trial for PRT120 in peanut allergy is planned or imminent.

Therapeutic areas: Immunology
Modalities: Oral immunotherapy (OIT)Combination probiotic allergen oral immunotherapy
Industry: Biotech

Drug pipeline

1 asset

PRT120

Unknown

Partnerships

Murdoch Children’s Research Institute—exclusive license to core technology.No major pharma partnerships disclosed.

Beyond the preview

Go deeper on Prota Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Prota Therapeutics.

Explore the full profile